Jeantet advises Turenne Santé in connection with its acquisition of a minority stake in Phodé
Paris, February 15, 2022 – Jeantet advised Turenne Santé in connection with its acquisition of a minority stake in Phodé.
This transaction allowed the exit of historical shareholders (including the investment fund Oraxys Environment 1) and the entry into the capital of the management team led by Damien Guillobez, who will become part of the group’s operational management.
With over €280 million under management, including more than €185 million for the FPCI Capital Santé 2, Turenne Santé supports healthcare companies in their development and transfer challenges. Turenne Groupe, one of France’s leading private equity firms, has been helping entrepreneurs with their innovation, development and transfer projects for more than 20 years.
Created in 1996 by Daniel Eclache, Phodé is the first laboratory specialized in olfaction and dedicated to the design, production and marketing of natural sensory solutions for the well-being of humans, animals and the environment.
Jeantet (Turenne Santé’s legal counsel): Thierry Brun (partner), Maxime Brotz (counsel), Maria Plakci and Pak-Hang Li (associates).
Oraxys was advised by Lamartine Conseil.
The management team and Aleph (Daniel Eclache) were advised by EY Société d’avocats.